SAN DIEGO, Feb. 14, 2017 /PRNewswire/ -- GenomeDx Biosciences today announced that oral and poster presentations featuring Decipher® Prostate Cancer Classifier tests, Genomics Resource Information Database (GRID®) and Bladder data will be given at the 2017 Genitourinary Cancers Symposium, held February 16 to 18, 2017, in Orlando, Florida.
Oral Presentations
Title: Evaluation of the Decipher Prostate Cancer Classifier to Predict Metastasis and Disease-Specific Mortality from Genomic Analysis of Diagnostic Prostate Needle Biopsy SpecimensDate: Thursday, February 16 (1:00 p.m. to 2:30 p.m. EST)Room: Gatlin Ballroom C, Level 1Presenter: Paul Nguyen, M.D., Dana-Farber Cancer Institute
Title: Luminal and Basal Subtyping of Prostate CancerDate: Thursday, February 16 (1:00 p.m. to 2:30 p.m. EST)Room: Gatlin Ballroom C, Level 1Presenter: Felix Feng, M.D., University of California, San Francisco
Title: Muscle-Invasive Bladder Cancer: Molecular Subtypes and Response to NeoadjuvantChemotherapyDate: Friday, February 17 (1:45 p.m. to 3:15 p.m. EST)Room: Gatlin Ballroom C, Level 1Presenter: Roland Seiler, M.D., University of British Columbia - Vancouver
Poster Presentations
Title: Evaluation of the Decipher Prostate Cancer Classifier to Predict Metastasis and Disease-Specific Mortality from Genomic Analysis of Diagnostic Prostate Needle Biopsy SpecimensDate: Thursday, February 16 (11:30 a.m. to 1:00 p.m. and 5:15 p.m. to 6:15 p.m. EST)Presentation Number: A5Room: Gatlin Ballroom B, Level 1Presenter: Paul Nguyen, M.D., Dana-Farber Cancer Institute
Title: Effect of Decipher Test on Adjuvant Treatment Decision-Making Among Men with High-Risk Pathology at Radical Prostatectomy: Results from a Multicenter Prospective PRO-IMPACT StudyDate: Thursday, February 16 (11:30 a.m. to 1:00 p.m. and 5:15 p.m. to 6:15 p.m. EST)Presentation Number: B11Room: Gatlin Ballroom B, Level 1Presenter: John L. Gore, M.D., M.S., University of Washington School of Medicine
Title: The Diverse Genomic Landscape of Low-Risk Prostate Cancer Date: Thursday, February 16 (11:30 a.m. to 1:00 p.m. and 5:15 p.m. to 6:15 p.m. EST)Presentation Number: D7Room: Gatlin Ballroom B, Level 1Presenter: Matthew Cooperberg, M.D., M.P.H., University of California, San Francisco
Title: Individual Patient Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High Risk Men Post-Prostatectomy to Predict Development of Metastatic DiseaseDate: Thursday, February 16 (11:30 a.m. to 1:00 p.m. and 5:15 p.m. to 6:15 p.m. EST)Presentation Number: E11Room: Gatlin Ballroom B, Level 1Presenter: Dan Spratt, M.D., University of Michigan
Title: Luminal and Basal Subtyping of Prostate CancerDate: Thursday, February 16 (11:30 a.m. to 1:00 p.m. and 5:15 p.m. to 6:15 p.m. EST)Presentation Number: A4Room: Gatlin Ballroom B, Level 1Presenter: Felix Feng, M.D., University of California, San Francisco
Title: Relationships between an Androgen Receptor Output Signature (ARoS), AR expression, and Poor Prostate Cancer Prognosis in RP TissuesDate: Thursday, February 16 (11:30 a.m. to 1:00 p.m. and 5:15 p.m. to 6:15 p.m. EST)Presentation Number: C1Room: Gatlin Ballroom B, Level 1Presenter: Mohammed Alshalalfa, Ph.D., GenomeDx Biosciences
Title: Genomic Classifier to Augment the Role of Pathological Features in Identifying Optimal Candidates for Adjuvant Radiation Therapy in Patients with Prostate Cancer: Development and Internal Validation of a Multivariable Prognostic ModelDate: Thursday, February 16 (11:30 a.m. to 1:00 p.m. and 5:15 p.m. to 6:15 p.m. EST)Presentation Number: E20Room: Gatlin Ballroom B, Level 1Presenter: Firas Abdollah, M.D., Henry Ford Health System
Title: Subtyping Muscle-Invasive Bladder Cancer to Assess Clinical Response to Trimodality TherapyDate: Friday, February 17 (12:15 p.m. to 1:45 p.m. and 6:00 p.m. to 7:00 p.m. EST)Presentation Number: D24Room: Gatlin Ballroom B, Level 1Presenter: Jason Efstathiou, M.D., Massachusetts General Hospital
Title: Muscle-Invasive Bladder Cancer: Molecular Subtypes and Response to Neoadjuvant ChemotherapyDate: Friday, February 17 (12:15 p.m. to 1:45 p.m. and 6:00 p.m. to 7:00 p.m. EST)Presentation Number: A3Room: Gatlin Ballroom B, Level 1Presenter: Roland Seiler, M.D., University of British Columbia – Vancouver
About Decipher GRID® and Decipher® Prostate Cancer Classifier Tests
GenomeDx's Decipher Genomics Resource Information Database (GRID) contains genomic profiles of thousands of tumors from patients with urological cancers, and is believed by GenomeDx to be the largest shared genomic expression database in urologic cancer as well as one of the world's largest global RNA expression databases using cloud-based analytics. GRID is a platform for interactive research collaboration, and may enable more rapid discovery, development, commercialization and adoption of new genomic solutions for key clinical questions in cancer treatment.
Derived from GRID, GenomeDx's Decipher Prostate Cancer Classifier tests are commercially available genomic tests that provide a genomic assessment of tumor aggressiveness for individual patients. Decipher Biopsy is indicated for men with localized prostate cancer at diagnosis, and Decipher Post-Op is indicated for men after prostate removal surgery. The Decipher tests are used by physicians to stratify patients into more accurate risk groups than determined by traditional diagnostic tools and to better determine which patients may be more likely to benefit from additional treatment. Each tumor analyzed with a Decipher test adds new data points to the GRID database, which is compiled into a Decipher GRID Profile that may reveal additional biological characteristics of the tumor for ongoing research purposes. Going beyond risk stratification, Decipher and GRID makes accessible genetic information for researchers to potentially better predict responses to therapy and more precisely guide treatment.
More information is available at www.deciphertest.com and www.deciphergrid.com.
About GenomeDx Biosciences
GenomeDx has reimagined the use of genomics as a platform for mass collaboration to improve treatment and outcomes of people with cancer. GenomeDx has built Decipher GRID, a large and fast-growing genomics database in urologic cancer that provides a foundation for open and interactive research collaboration and knowledge creation. Using Decipher GRID and machine learning to analyze vast amounts of genomic data, GenomeDx develops and commercializes proprietary clinical tests that are intended to provide more accurate and useful diagnostic information than traditional diagnostic tools or existing genomic tests. GenomeDx's Decipher Biopsy and Decipher Post-Op are commercially available prostate cancer genomic tests that provide an assessment of tumor aggressiveness based on a patient's unique genomic profile. GenomeDx is headquartered in Vancouver, British Columbia and operates a clinical laboratory in San Diego, California.
Learn more at www.GenomeDx.com
Advertisement
Oral Presentations
Title: Evaluation of the Decipher Prostate Cancer Classifier to Predict Metastasis and Disease-Specific Mortality from Genomic Analysis of Diagnostic Prostate Needle Biopsy SpecimensDate: Thursday, February 16 (1:00 p.m. to 2:30 p.m. EST)Room: Gatlin Ballroom C, Level 1Presenter: Paul Nguyen, M.D., Dana-Farber Cancer Institute
Advertisement
Title: Luminal and Basal Subtyping of Prostate CancerDate: Thursday, February 16 (1:00 p.m. to 2:30 p.m. EST)Room: Gatlin Ballroom C, Level 1Presenter: Felix Feng, M.D., University of California, San Francisco
Title: Muscle-Invasive Bladder Cancer: Molecular Subtypes and Response to NeoadjuvantChemotherapyDate: Friday, February 17 (1:45 p.m. to 3:15 p.m. EST)Room: Gatlin Ballroom C, Level 1Presenter: Roland Seiler, M.D., University of British Columbia - Vancouver
Poster Presentations
Title: Evaluation of the Decipher Prostate Cancer Classifier to Predict Metastasis and Disease-Specific Mortality from Genomic Analysis of Diagnostic Prostate Needle Biopsy SpecimensDate: Thursday, February 16 (11:30 a.m. to 1:00 p.m. and 5:15 p.m. to 6:15 p.m. EST)Presentation Number: A5Room: Gatlin Ballroom B, Level 1Presenter: Paul Nguyen, M.D., Dana-Farber Cancer Institute
Title: Effect of Decipher Test on Adjuvant Treatment Decision-Making Among Men with High-Risk Pathology at Radical Prostatectomy: Results from a Multicenter Prospective PRO-IMPACT StudyDate: Thursday, February 16 (11:30 a.m. to 1:00 p.m. and 5:15 p.m. to 6:15 p.m. EST)Presentation Number: B11Room: Gatlin Ballroom B, Level 1Presenter: John L. Gore, M.D., M.S., University of Washington School of Medicine
Title: The Diverse Genomic Landscape of Low-Risk Prostate Cancer Date: Thursday, February 16 (11:30 a.m. to 1:00 p.m. and 5:15 p.m. to 6:15 p.m. EST)Presentation Number: D7Room: Gatlin Ballroom B, Level 1Presenter: Matthew Cooperberg, M.D., M.P.H., University of California, San Francisco
Title: Individual Patient Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High Risk Men Post-Prostatectomy to Predict Development of Metastatic DiseaseDate: Thursday, February 16 (11:30 a.m. to 1:00 p.m. and 5:15 p.m. to 6:15 p.m. EST)Presentation Number: E11Room: Gatlin Ballroom B, Level 1Presenter: Dan Spratt, M.D., University of Michigan
Title: Luminal and Basal Subtyping of Prostate CancerDate: Thursday, February 16 (11:30 a.m. to 1:00 p.m. and 5:15 p.m. to 6:15 p.m. EST)Presentation Number: A4Room: Gatlin Ballroom B, Level 1Presenter: Felix Feng, M.D., University of California, San Francisco
Title: Relationships between an Androgen Receptor Output Signature (ARoS), AR expression, and Poor Prostate Cancer Prognosis in RP TissuesDate: Thursday, February 16 (11:30 a.m. to 1:00 p.m. and 5:15 p.m. to 6:15 p.m. EST)Presentation Number: C1Room: Gatlin Ballroom B, Level 1Presenter: Mohammed Alshalalfa, Ph.D., GenomeDx Biosciences
Title: Genomic Classifier to Augment the Role of Pathological Features in Identifying Optimal Candidates for Adjuvant Radiation Therapy in Patients with Prostate Cancer: Development and Internal Validation of a Multivariable Prognostic ModelDate: Thursday, February 16 (11:30 a.m. to 1:00 p.m. and 5:15 p.m. to 6:15 p.m. EST)Presentation Number: E20Room: Gatlin Ballroom B, Level 1Presenter: Firas Abdollah, M.D., Henry Ford Health System
Title: Subtyping Muscle-Invasive Bladder Cancer to Assess Clinical Response to Trimodality TherapyDate: Friday, February 17 (12:15 p.m. to 1:45 p.m. and 6:00 p.m. to 7:00 p.m. EST)Presentation Number: D24Room: Gatlin Ballroom B, Level 1Presenter: Jason Efstathiou, M.D., Massachusetts General Hospital
Title: Muscle-Invasive Bladder Cancer: Molecular Subtypes and Response to Neoadjuvant ChemotherapyDate: Friday, February 17 (12:15 p.m. to 1:45 p.m. and 6:00 p.m. to 7:00 p.m. EST)Presentation Number: A3Room: Gatlin Ballroom B, Level 1Presenter: Roland Seiler, M.D., University of British Columbia – Vancouver
About Decipher GRID® and Decipher® Prostate Cancer Classifier Tests
GenomeDx's Decipher Genomics Resource Information Database (GRID) contains genomic profiles of thousands of tumors from patients with urological cancers, and is believed by GenomeDx to be the largest shared genomic expression database in urologic cancer as well as one of the world's largest global RNA expression databases using cloud-based analytics. GRID is a platform for interactive research collaboration, and may enable more rapid discovery, development, commercialization and adoption of new genomic solutions for key clinical questions in cancer treatment.
Derived from GRID, GenomeDx's Decipher Prostate Cancer Classifier tests are commercially available genomic tests that provide a genomic assessment of tumor aggressiveness for individual patients. Decipher Biopsy is indicated for men with localized prostate cancer at diagnosis, and Decipher Post-Op is indicated for men after prostate removal surgery. The Decipher tests are used by physicians to stratify patients into more accurate risk groups than determined by traditional diagnostic tools and to better determine which patients may be more likely to benefit from additional treatment. Each tumor analyzed with a Decipher test adds new data points to the GRID database, which is compiled into a Decipher GRID Profile that may reveal additional biological characteristics of the tumor for ongoing research purposes. Going beyond risk stratification, Decipher and GRID makes accessible genetic information for researchers to potentially better predict responses to therapy and more precisely guide treatment.
More information is available at www.deciphertest.com and www.deciphergrid.com.
About GenomeDx Biosciences
GenomeDx has reimagined the use of genomics as a platform for mass collaboration to improve treatment and outcomes of people with cancer. GenomeDx has built Decipher GRID, a large and fast-growing genomics database in urologic cancer that provides a foundation for open and interactive research collaboration and knowledge creation. Using Decipher GRID and machine learning to analyze vast amounts of genomic data, GenomeDx develops and commercializes proprietary clinical tests that are intended to provide more accurate and useful diagnostic information than traditional diagnostic tools or existing genomic tests. GenomeDx's Decipher Biopsy and Decipher Post-Op are commercially available prostate cancer genomic tests that provide an assessment of tumor aggressiveness based on a patient's unique genomic profile. GenomeDx is headquartered in Vancouver, British Columbia and operates a clinical laboratory in San Diego, California.
Learn more at www.GenomeDx.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/genomedxs-decipher-prostate-grid-and-bladder-data-to-be-featured-in-multiple-presentations-at-the-2017-genitourinary-cancers-symposium-300406724.html
SOURCE GenomeDx Biosciences
